Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer

  title={Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ER$\beta$) in human prostate cancer},
  author={Yasuhiro Nakamura and Saulo J.A. Felizola and Yumi Kurotaki and Fumiyoshi Fujishima and Keely May McNamara and Takashi Suzuki and Yoichi Arai and Hironobu Sasano},
  journal={The Prostate},
Estrogen receptor beta (ERβ) has been demonstrated to be expressed in prostate carcinoma cells and estrogen signals through ERβ to act as a tumor suppressor in prostate cancer patients. ERβ is thought to regulate the cell cycle of prostate carcinoma cells by controlling the expression of cell cycle regulators including cyclin D1 (CCND1). This interaction is of particular interest as CCND1 has been implicated in the development of prostate cancer. 
Estrogen receptor β in cancer: to β(e) or not to β(e)?
While ERβ exhibits anti-tumor activity in breast, ovarian, and prostate cancer, its expression is associated with disease progression and worse prognosis in lung cancer.
Targeting Androgen/Estrogen Receptors Crosstalk in Cancer.
ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells
It is found that loss of ZFHX3 increased cell proliferation and MYC expression, and downregulation of MYC was necessary for ZFHx3 to inhibit cell proliferation in the same cell lines, and this findings establish MYC repression as a mechanism for ZEHX3’s tumor suppressor activity and ZFH X3 as an indispensable factor for ERβ‘s tumor suppressionor activity in prostate cancer cells.
Estrogen Receptor Beta (ERβ) Mediated-CyclinD1 Degradation via Autophagy Plays an Anti-Proliferation Role in Colon Cells
Results indicate that ERβ-mediated CyclinD1 degradation can inhibit colon cancer cell growth via autophagy, and ERβ could inhibit the mammalian target of rapamycin or activate Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (BNIP3) to promote Autophagy in HCT116.
The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-β in the progression of LNCaP prostate cancer models.
Results indicate that DBP may induce the growth of LNCaP prostate cancer by acting on the crosstalk between TGF-β and ER signaling pathways.
Oestrogens and oestrogen receptors in prostate cancer
This review summarizes the current knowledge on molecular mechanisms through which oestrogens are involved in prostate cancer development and focused on commonly alternated molecular signalling pathways contributing to tumourgenesis in prostatecancer.
Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome
Significant prognostic roles of ERα, ERβ and aromatase were discovered in the in PCa specimens of a large multicenter cohort of patients treated with radical prostatectomy.
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines
The results demonstrate that ERβ is expressed in melanoma cell lines and that ER β agonists differentially regulate the proliferation of these cells, confirming the notion that melanoma is a heterogeneous tumor and that genetic profiling is mandatory for the development of effective personalized therapeutic approaches for melanoma patients.
Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation


Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors
The cyclin D1 gene is amplified and/or overexpressed in several types of human cancer, including cancers of the breast, esophagus, head, and neck. However, the role of cyclin D1 in prostate cancer
Expression of ERα and ERβ in prostate cancer
To elucidate the significance of these receptors, expression of both ERα and ERβ was measured in benign and malignant prostate tumors, as well as in cell lines.
Involvement of estrogen receptors in prostatic diseases
  • H. Kawashima, T. Nakatani
  • Biology, Chemistry
    International journal of urology : official journal of the Japanese Urological Association
  • 2012
Estrogen receptor-mediated signaling in the prostate is essential together with the androgen receptor‐mediated pathway, providing a new therapeutic target for prostatic diseases.
Expression of ERalpha and ERbeta in prostate cancer.
It is unlikely that alterations in the expression of either ER are commonly involved in the progression of prostate cancer, as measured in benign and malignant prostate tumors and cell lines.
Overexpression of cyclin D1 is rare in human prostate carcinoma
Overexpression of cyclin D1 has been documented in a number of human cancers and can contribute to cellular transformation and abnormal proliferation.
Estrogen Regulates Tumor Growth Through a Nonclassical Pathway that Includes the Transcription Factors ERβ and KLF5
It is demonstrated that the estrogen receptor β (ERβ) mediates inhibition by the antiestrogen ICI 182,780 (ICI) and its enhancement by estrogen, and affects prostate tumor growth through ERβ-mediated regulation of KLF5.
Nuclear receptor DAX1 in human prostate cancer: a novel independent biological modulator.
DAX1 immunoreactivity is considered a new biological modulator of human prostate cancer, but independent to the status of sex steroid receptors inhuman prostate cancer tissues.
AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells
A role for AIB1 is established in AI-resistant breast cancer and a new mechanism of ERα/AIB1 gene regulation which could contribute to the development of an aggressive tumor phenotype is described.
NGX6 inhibits AP-1 and Ets-1 expression and down-regulates cyclin D1 in human colorectal cancer.
It is proposed that NGX6 expression is lost in the multistep process of human colorectal carcinogenesis, which can inhibit the expression of transcription factors AP-1 and Ets-1, and down-regulate the transcriptional activity of the cyclin D1 promoter in human CRC.